New User:

Forgot your password?

Stock Market & Financial Investment News

Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 20, 2015
13:45 EDTSQNMIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
08:21 EDTMDASMedAssets upgraded to Buy from Hold at Evercore ISI
Evercore ISI upgraded MedAssets to Buy based on recent share underperformance. Price target lowered to $21 from $24.
06:37 EDTMDASMedAssets upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
January 16, 2015
10:01 EDTMDASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:54 EDTMDASMedAssets downgraded at RW Baird on expectations for guidance miss
Subscribe for More Information
06:17 EDTMDASMedAssets downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
January 15, 2015
13:47 EDTAMEDAmedisys sees '15 impact from Medicare Home Health rule more moderate
Amedisys announced that it expects the impact of the 2015 Medicare Home Health Prospective Payment System Final Rule to be more moderate than previously anticipated. Previously, the company had disclosed that it expected an impact of -0.80% relative to 2014 Medicare pricing; however, after further analysis, the company now expects the 2015 pricing to be relatively unchanged from 2014.
January 14, 2015
11:45 EDTIMGNImmunoGen discloses triggering of $5M milestone payment from Novartis
Subscribe for More Information
10:33 EDTAMEDAmedisys targets market share capture in home health in 2015
The company says hospice growth will be key as it seeks to reverse ADC declines in 2015. Targets incremental efficiencies in cost of revenue and field and corporate G&A. Comments taken from slides for January Investor Presentation.
January 13, 2015
11:08 EDTHTWRHeartWare CEO comments on clinical progress
Subscribe for More Information
11:07 EDTHTWRHeartWare sees FY14 revenue approximately $278M, consensus $276.55M
"Our full-year revenue growth of 34% for 2014 above 2013 reflects the strong market penetration we have experienced to date for the HeartWare Ventricular Assist System in both the U.S. and international markets," said Doug Godshall, President and CEO. "Fourth quarter 2014 unit sales increased by approximately 9 percent sequentially compared to the third quarter of 2014, a key driver of our strong revenue performance."
11:06 EDTHTWRHeartWare sees Q4 revenue approximately $73M, consensus $71.24M
Subscribe for More Information
09:10 EDTMDASMedAssets sees FY14 adjusted EPS near midpoint of $1.34-$1.38 range
Sees FY14 adjusted EBITDA near low end of $234M-$238M range. Sees consolidated net revenue at midpoint of $715M-$721M range, consensus $716.44M. Says $28M in net revenue recognized in FY14 will not recur in FY15 due to conclusion of Barnabas RCM outsourcing agreement on December 31. Comments from slides that will be presented at the JP Morgan Healthcare Conference.
08:36 EDTHTWRHeartWare announces first patient implant in HVAD LATERAL Study
HeartWare International announced the first patient implant in the HVAD LATERAL Study, a U.S. Investigational Device Exemption, or IDE, clinical trial in which the HeartWare Ventricular Assist System, featuring the HVAD Pump, is implanted through a less-invasive thoracotomy procedure in patients with end-stage heart failure who are awaiting a heart transplant.
07:42 EDTMDAS, HTWRJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
15:40 EDTSQNMSequenom Q4 preliminary results disappointing, says Piper Jaffray
Subscribe for More Information
15:27 EDTSQNMSequenom sees FY15 accessioned tests above 200K
Subscribe for More Information
15:25 EDTSQNMSequenom sees Q4 revenue $37M, consensus $44.6M
Subscribe for More Information
15:21 EDTSQNMSequenom sees FY14 revenue $151M, consensus $160.7M
Sequenom reported FY14 preliminary revenue of $151M earlier in slides for its upcoming presentation at the JP Morgan Healthcare Conference. The company said in the slides that it had reduced its cash burn from $107M in FY13 to $37M in FY14 and ended FY14 with approximately $94M in cash. The company reported FY14 NIPT accessioned tests of 162. Sequenom shares are down 1% in afternoon trading after this morning's disclosure of the conference slides.
January 11, 2015
10:31 EDTIMGNImmunoGen lays out 2015 product pipeline expectations
ImmunoGen announced its expectations for its product pipeline in 2015 that management will be discussing at the J.P. Morgan Healthcare Conference starting tomorrow. For IMGN853, ImmunoGen expects to present updated clinical findings in Q2 as well as the initiation of Phase II testing in FRá-positive ovarian cancer or endometrial cancer, or both. For IMGN529, the company expects the selection of recommended Phase II dose in the first half of 2015 as well as the start of initial efficacy testing, including as a treatment for relapsed/refractory diffuse large B-cell lymphoma and for chronic lymphocytic leukemia in Q2 or Q3. For IMGN779, the company expects the submission of an Investigational New Drug Application in the second half of 2015. ImmunoGen noted that it ended the quarter with approximately $107M in cash and marketable securities, and had no debt.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use